Manage Your Liver
Q:

The threat of liver cancer remains despite successful HCV treatment

The threat of liver cancer remains despite successful HCV treatment
A:

Hepatocellular carcinoma (HCC) or liver cancer is currently the third leading cause of cancer deaths worldwide, affecting over 500,000 people. One of the major risks for the development of HCC is persistent infection with hepatitis C virus (HCV) and cirrhosis. Despite the recent development of direct-acting antivirals (DAAs), which has given hope to millions of liver disease patients around the world as they have made clearing the hepatitis C virus possible, the burden of HCC and cirrhosis caused by hepatitis C is likely to continue to grow.

 

Theoretically, the high success rates of DAAs now used to treat patients with HCV will lower the number of patients that would progress to cirrhosis and HCC. However, a study conducted by the University of Washington - School of Medicine predicted that the incidence of both cirrhosis and HCC are likely to continue to rise in the United States until 2021. [1] This is because DAAs are only designed to eradicate the virus; they do not help to restore liver health and normal liver function. Therefore even after successful DAA treatment, the damage that has occurred to the liver cannot be undone or wholly reversed without post treatment recovery care. People who have undergone treatment remain at elevated risk of HCC, especially those who have suffered many years of liver damage as a result of hepatitis C. The longer a patient has been infected with HCV, the greater the chance for abnormal liver cells to transform into cancer cells. [2]

 

This is supported by research, which has shown that a long-term risk for liver cancer remained in their study participants, even in some of those who have achieved sustained virological response (SVR). According to a clinical study, 5% of participants who achieved SVR subsequently developed liver cancer over an average observation period of five years. Moreover, among participants who did not experience SVR, cases of liver cancer were at least twice as high as among participants who did achieve SVR. [3]

 

In other words, achieving SVR does not indicate that damaged liver cells are healed and the risk of progression to HCC is relieved. Post-treatment regular monitoring and protective measures are needed to reduce the risk of developing tumours. To safeguard the liver from HCC, recovery of liver cells and long term protection is required. This can be achieved through YHK, a scientifically based natural liver therapy from Japan. Research has proven that it helps with the repair of damaged liver cells and regeneration of healthy liver cells. In addition, YHK has been shown to exert protective anti-tumour effect that helps to prevent liver cancer. Also, it has been scientifically proven to decrease the proliferation rate of human liver cancer cell growth and enhance the oxidative stress of liver cancer cells, which significantly increases apoptosis (programmed cell death). [4][5]

 

DAAs are no doubt a big step forward in the treatment of hepatitis C, but let’s not forget our ultimate aim and wish: ensuring liver health, good liver function, and preventing liver cancer.

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
Read Linda's story. ================ “I was diagnosed with a fatty liver and tested for PBC, Primary Biliary Cholangitis and the hepatologist told me there was nothing I could do except to lose weight. I was determined to prove him wrong and researched fatty liver and PBC. I came across your website and ordered the YHK tablets. Since both my AST and ALT were elevated however not extremely high, I only took one tablet upon rising on an empty stomach and one
A:
DAAs (direct-acting antivirals) are the latest hepatitis C treatment option introduced to the market, their high price tag has caused great controversy since their introduction but recently people are worried about something else – DAA’s possible side effects. Recent findings revealed that DAAs could lead to aggressive growth of hepatocellular carcinoma (HCC) or liver cancer. In a Spanish study, investigators noted a "high rate of cancer recurrence" after
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
YHK has significant effect in stopping liver inflammation; it can enhance the recovery of liver health and protect liver cells. Those who have experienced YHK often have these questions in mind: Why is YHK so different from other liver medicines and supplements? Why is it possible to have such unprecedented effects? The answer seems magical, but in fact, it is not complicated - Because YHK possesses a perfect balance.   To explain this, we must first point out that YH
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us